Postmenopausal hormone therapy offers no protection against heart attacks.
D000368:Aged; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D004311:Double-Blind Method; D004338:Drug Combinations; D004967:Estrogens / Q000008:administration & dosage; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005705:Gallbladder Diseases / Q000453:epidemiology / Q000601:surgery; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D010919:Placebos; D017698:Postmenopause; D045167:Progesterone Congeners / Q000008:administration & dosage; D011372:Progestins / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology; D013997:Time Factors
D004338:Drug Combinations; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D010919:Placebos; D045167:Progesterone Congeners; D011372:Progestins; D017258:Medroxyprogesterone Acetate